Sorrento OK'd For Alternative $110M Ch. 11 Stock Sale
Bankrupt drug developer Sorrento Therapeutics received a Texas court's approval Tuesday for subsidiary Scilex Holding Co. to buy its own stock back from its parent for $110 million after the original...To view the full article, register now.
Already a subscriber? Click here to view full article